IDYA logo

IDEAYA Biosciences (IDYA)

Profile

Full Name

IDEAYA Biosciences, Inc.

Ticker Symbol

IDYA

Exchange

NASDAQ

Country

United States

IPO

May 23, 2019

Indexes

Not included

Employees

131

Key Details

Price

$17.08(+5.56%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$7.00M(-70.07% YoY)

Annual EPS

-$3.36(-71.43% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Feb 14, 25 Stephens & Co.
Overweight
Jan 15, 25 RBC Capital
Outperform
Jan 13, 25 Cantor Fitzgerald
Overweight
Dec 17, 24 Wedbush
Outperform
Dec 17, 24 Cantor Fitzgerald
Overweight
Nov 18, 24 Stephens & Co.
Overweight
Nov 5, 24 Leerink Partners
Market Perform
Oct 29, 24 Oppenheimer
Outperform
Oct 24, 24 UBS
Buy
Sep 24, 24 Wedbush
Outperform

Institutional Ownership

  • What is the ticker symbol for IDEAYA Biosciences?
  • Does IDEAYA Biosciences pay dividends?
  • What sector is IDEAYA Biosciences in?
  • What industry is IDEAYA Biosciences in?
  • What country is IDEAYA Biosciences based in?
  • When did IDEAYA Biosciences go public?
  • Is IDEAYA Biosciences in the S&P 500?
  • Is IDEAYA Biosciences in the NASDAQ 100?
  • Is IDEAYA Biosciences in the Dow Jones?
  • When was IDEAYA Biosciences's last earnings report?
  • When does IDEAYA Biosciences report earnings?
  • Should I buy IDEAYA Biosciences stock now?

What is the ticker symbol for IDEAYA Biosciences?

The ticker symbol for IDEAYA Biosciences is NASDAQ:IDYA

Does IDEAYA Biosciences pay dividends?

No, IDEAYA Biosciences does not pay dividends

What sector is IDEAYA Biosciences in?

IDEAYA Biosciences is in the Healthcare sector

What industry is IDEAYA Biosciences in?

IDEAYA Biosciences is in the Biotechnology industry

What country is IDEAYA Biosciences based in?

IDEAYA Biosciences is headquartered in United States

When did IDEAYA Biosciences go public?

IDEAYA Biosciences's initial public offering (IPO) was on May 23, 2019

Is IDEAYA Biosciences in the S&P 500?

No, IDEAYA Biosciences is not included in the S&P 500 index

Is IDEAYA Biosciences in the NASDAQ 100?

No, IDEAYA Biosciences is not included in the NASDAQ 100 index

Is IDEAYA Biosciences in the Dow Jones?

No, IDEAYA Biosciences is not included in the Dow Jones index

When was IDEAYA Biosciences's last earnings report?

IDEAYA Biosciences's most recent earnings report was on Feb 13, 2025

When does IDEAYA Biosciences report earnings?

The next expected earnings date for IDEAYA Biosciences is May 7, 2025

Should I buy IDEAYA Biosciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page